The role of C-reactive protein (CRP) and statin treatment in reducing cardiovascular risk.
Chin
Jaclynn
J
Sioux Falls Veterans Administration Medical Center, USA.
D002097:C-Reactive Protein / Q000032:analysis* / Q000187:drug effects; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D005464:Fluorobenzenes / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011322:Primary Prevention; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein